“PROTINUS” (lat. forward, further”) is the name of the project with which the biopharmaceutical company CSL Behring will significantly increase the production capacity of immunoglobulin at its site. GEA received the order for the process plant, the heart of the facility. The two additional production lines will enable a further 90,000 patients per year to be supplied with life-saving drugs. Thanks to the good cooperation of all parties involved in the project, it was possible to continue…
COMMENTS